Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Mark A. Socinski; Robert M. Jotte; Federico Cappuzzo; Francesco Orlandi; Daniil Stroyakovskiy; Naoyuki Nogami; Delvys Rodríguez‐Abreu; Denis Moro‐Sibilot; Christian A. Thomas; Fabrice Barlési; Gene Grant Finley; Claudia Kelsch; Anthony Lee; Shelley Coleman; Yu Deng; Yijing Shen; Marcin Kowanetz; Ariel López-Chávez; Alan Sandler; Martin Reck

doi:10.1056/nejmoa1716948

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

The addition of atezolizumab to bevacizumab plus chemotherapy significantly improved progression-free survival and overall survival among patients with metastatic nonsquamous NSCLC, regardless of PD-L1 expression and EGFR or ALK genetic alteration status. (Funded by F. Hoffmann-La Roche/Genentech; IMpower150 ClinicalTrials.gov number, NCT02366143 .).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Socinski et al. (2018) studied this question.

synapsesocial.com/papers/6985ef823b00292770426f41 https://doi.org/10.1056/nejmoa1716948

View Full Paper

Ask AI

Bookmark

Share

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Ask about this paper

Abstract

Discussion

Cite This Study

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading